Treatment of cyr61- and vegf-mediated conditions

Abstract

The invention relates generally to the treatment of CYR61- and VEGF-mediated conditions and, more particularly to the treatment of such conditions by administering to an individual a CYR61 downregulator. In one embodiment, the invention provides a method of treating a CYR61-mediated condition in an individual in need of such treatment, the method comprising: administering to the individual an effective amount of at least one CYR61 downregulator (CYR61DR), wherein the effective amount is an amount sufficient to decrease expression of the CYR61 gene in the individual.

What is claimed is: 
     
         1 . A method of treating a VEGF-mediated condition in an individual in need of such treatment, the method comprising:
 administering to the individual an effective amount of at least one CYR61 downregulator (CYR61DR),   wherein the effective amount is an amount sufficient to decrease expression of the VEGF gene in the individual.   
     
     
         2 . The method of  claim 1 , wherein the at least one CYR61DR is selected from a group consisting of: anthracyclines and statins. 
     
     
         3 . The method of  claim 2 , wherein the at least one CYR61DR includes at least one anthracycline selected from a group consisting of: doxorubicin, daunorubicin, epirubicin, idarubicin, valrubicin, and mitoxantrone. 
     
     
         4 . The method of  claim 2 , wherein the at least one CYR61DR includes at least one statin selected from a group consisting of: simvastatin, pravastatin, fluvastatin, atrovastatin, cerivastatin, lovastatin, mevastatin, pitavastatin, and rosuvastatin. 
     
     
         5 . The method of  claim 1 , wherein administering includes intravitreally administering. 
     
     
         6 . The method of  claim 1 , wherein administering includes orally administering. 
     
     
         7 . A method of treating a VEGF-mediated condition in an individual in need of such treatment, the method comprising:
 administering to the individual an effective amount of at least one CYR61 downregulator (CYR61DR),   wherein the effective amount is an amount sufficient to decrease expression of the CYR61 gene and the VEGF gene in the individual.